Lantern Pharma Inc. Interest Income, Other
Lantern Pharma Inc. (LTRN) reported Interest Income, Other of $30.08 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-14
- Lantern Pharma Inc. interest income, other for the quarter ending 2026-06-30 was $30.08K, a 73.79% decline year-over-year.
- Lantern Pharma Inc. interest income, other for the quarter ending 2026-03-31 was $42.16K, a 71.85% decline year-over-year.
- Lantern Pharma Inc. interest income, other for the quarter ending 2025-12-31 was $72.47K, a 55.09% decline year-over-year.
- Lantern Pharma Inc. interest income, other for the quarter ending 2025-09-30 was $100.92K, a 47.26% decline year-over-year.
- Lantern Pharma Inc. interest income, other for fiscal 2025 was $437.93K, a 41.01% decline from fiscal 2024.
- Lantern Pharma Inc. interest income, other for fiscal 2024 was $742.36K, a 3.01% decline from fiscal 2023.
- Lantern Pharma Inc. interest income, other for fiscal 2023 was $765.39K, a 274.54% increase from fiscal 2022.
- Lantern Pharma Inc. interest income, other for fiscal 2022 was $204.35K, a 200.84% increase from fiscal 2021.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.08K 10-Q · filed 2026-08-14 | $72.24K 10-Q · filed 2026-08-14 | $144.71K derived: sum of 3 quarters · filed 2026-08-14 | $245.63K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $42.16K 10-Q · filed 2026-05-15 | $114.64K derived: sum of 2 quarters · filed 2026-05-15 | $215.56K derived: sum of 3 quarters · filed 2026-05-15 | $330.30K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $72.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $173.40K derived: sum of 2 quarters · filed 2026-03-30 | $288.14K derived: sum of 3 quarters · filed 2026-08-14 | $437.93K 10-K · filed 2026-03-30 |
| 2025-09-30 | $100.92K 10-Q · filed 2025-11-12 | $215.67K derived: sum of 2 quarters · filed 2026-08-14 | $365.46K 10-Q · filed 2025-11-12 | $526.85K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $114.75K 10-Q · filed 2026-08-14 | $264.54K 10-Q · filed 2026-08-14 | $425.93K derived: sum of 3 quarters · filed 2026-08-14 | $617.28K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $149.79K 10-Q · filed 2026-05-15 | $311.18K derived: sum of 2 quarters · filed 2026-05-15 | $502.54K derived: sum of 3 quarters · filed 2026-05-15 | $691.20K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $161.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $352.75K derived: sum of 2 quarters · filed 2026-03-30 | $541.40K derived: sum of 3 quarters · filed 2026-03-30 | $742.36K 10-K · filed 2026-03-30 |
| 2024-09-30 | $191.35K 10-Q · filed 2025-11-12 | $380.01K derived: sum of 2 quarters · filed 2025-11-12 | $580.96K 10-Q · filed 2025-11-12 | $848.35K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $188.66K 10-Q · filed 2025-08-13 | $389.61K 10-Q · filed 2025-08-13 | $657.00K derived: sum of 3 quarters · filed 2025-08-13 | $903.39K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $200.95K 10-Q · filed 2025-05-15 | $468.34K derived: sum of 2 quarters · filed 2025-05-15 | $714.73K derived: sum of 3 quarters · filed 2025-05-15 | $832.56K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $267.39K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $513.78K derived: sum of 2 quarters · filed 2025-03-27 | $631.61K derived: sum of 3 quarters · filed 2025-03-27 | $765.39K 10-K · filed 2025-03-27 |
| 2023-09-30 | $246.39K 10-Q · filed 2024-11-07 | $364.22K derived: sum of 2 quarters · filed 2024-11-07 | $498.00K 10-Q · filed 2024-11-07 | $572.68K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $117.82K 10-Q · filed 2024-08-08 | $251.60K 10-Q · filed 2024-08-08 | $326.29K derived: sum of 3 quarters · filed 2024-08-08 | $378.51K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $133.78K 10-Q · filed 2024-05-09 | $208.47K derived: sum of 2 quarters · filed 2024-05-09 | $260.69K derived: sum of 3 quarters · filed 2024-05-09 | $315.72K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $74.68K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $126.91K derived: sum of 2 quarters · filed 2024-03-18 | $181.93K derived: sum of 3 quarters · filed 2024-03-18 | $204.35K 10-K · filed 2024-03-18 |
| 2022-09-30 | $52.22K 10-Q · filed 2023-11-08 | $107.25K derived: sum of 2 quarters · filed 2023-11-08 | $129.67K 10-Q · filed 2023-11-08 | $72.49K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $55.03K 10-Q · filed 2023-08-09 | $77.45K 10-Q · filed 2023-08-09 | $20.27K derived: sum of 3 quarters · filed 2023-08-09 | $97.49K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $22.42K 10-Q · filed 2023-05-09 | -$34.76K derived: sum of 2 quarters · filed 2023-05-09 | $42.46K derived: sum of 3 quarters · filed 2023-05-09 | $90.35K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$57.18K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $20.04K derived: sum of 2 quarters · filed 2023-03-20 | $67.93K derived: sum of 3 quarters · filed 2023-03-20 | $67.93K 10-K · filed 2023-03-20 |
| 2021-09-30 | $77.22K 10-Q · filed 2022-11-07 | $125.11K derived: sum of 2 quarters · filed 2022-11-07 | $125.11K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $47.89K 10-Q · filed 2022-08-08 | $47.89K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |